Bronwen Bastone Sells 3,126 Shares of Enfusion, Inc. (NYSE:ENFN) Stock

Enfusion, Inc. (NYSE:ENFN) insider Bronwen Bastone sold 3,126 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total transaction of $35,573.88. Following the transaction, the insider now owns 221,875 shares in the company, valued at approximately $2,524,937.50. This trade represents a 1.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Bronwen Bastone also recently made the following trade(s):

• On Monday, March 3rd, Bronwen Bastone sold 2,064 shares of Enfusion stock. The stock was sold at an average price of $11.48, for a total transaction of $23,694.72.
• On Tuesday, January 7th, Bronwen Bastone sold 809 shares of Enfusion stock. The stock was sold at an average price of $10.13, for a total transaction of $8,195.17.

Enfusion Price Performance

Shares of NYSE ENFN opened at $11.24 on Friday. Enfusion, Inc. has a 12-month low of $7.83 and a 12-month high of $11.80. The company has a market capitalization of $1.44 billion, a PE ratio of 280.95, a price-to-earnings-growth ratio of 1.85 and a beta of 0.95. The firm’s 50-day moving average is $10.98 and its two-hundred day moving average is $9.89.

Enfusion (NYSE:ENFN) last announced its quarterly earnings results on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The business had revenue of $52.94 million during the quarter, compared to analysts’ expectations of $53.98 million. On average, analysts forecast that Enfusion, Inc. will post 0.06 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on ENFN. Stifel Nicolaus boosted their price objective on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. William Blair reissued a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. Finally, Piper Sandler boosted their price objective on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a report on Monday, December 23rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Enfusion presently has a consensus rating of “Hold” and an average price target of $11.13.

Institutional Trading of Enfusion

Institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC lifted its holdings in shares of Enfusion by 7.3% in the third quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock valued at $9,770,000 after purchasing an additional 70,367 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Enfusion by 6.7% during the third quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock valued at $9,265,000 after buying an additional 61,032 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Enfusion by 612.4% during the third quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company’s stock valued at $1,974,000 after buying an additional 178,821 shares during the period. Barclays PLC lifted its stake in shares of Enfusion by 251.4% during the third quarter. Barclays PLC now owns 86,039 shares of the company’s stock valued at $817,000 after buying an additional 61,554 shares during the period. Finally, PDT Partners LLC purchased a new position in shares of Enfusion during the third quarter valued at approximately $867,000. Hedge funds and other institutional investors own 81.05% of the company’s stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.